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Toward a Better Understanding of...

Characterizing Effects of Pevonedistat
in Myeloproliferative Neoplasms
Abigail J. Wong
Mentor: Stephen Oh
Myeloproliferative neoplasms (MPNs) are hematologic malignancies that cause
uncontrolled blood cell growth and can progress to secondary acute myeloid leukemia
(sAML). While there are therapies for AML and MPN patients, only a fraction of
them are suitable to the individual, and the progress of standard chemotherapy has
remained largely stagnant over the past few decades. Therefore, the investigation of
MPN drug candidates such as pevonedistat is imperative. Pevonedistat is a NEDD8
activating enzyme inhibitor currently in clinical trials for AML. The inhibitor is known
to impede NF-kB signaling as well as other signaling pathways associated with MPN
pathogenesis; therefore, it is crucial to characterize the effects of pevonedistat on a
variety of pathways. While the JAK-STAT pathway is primarily associated with AML
and myelofibrosis, inhibition of JAK2 does not completely diminish MPN pathogenesis.
Therefore, it is likely that activation of other signaling processes drive cell proliferation
in addition to JAKSTAT. Previous studies in the Oh Lab have shown that the NF-kB
pathway is hyperactivated in sAML and MF hematopoietic stem and progenitor cells
(HSPC), identifying the NF-kB pathway as a potential target of pevonedistat. We have
found that pevonedistat lowers cell viability in human erythroleukemia (HEL) cell line in
a dose-dependent manner. Furthermore, pevonedistat in combination with JNK-IN-8,
an inhibitor of the JNK-AP1 pathway, lowers cell viability in an additive fashion. The
combination of pevonedistat and JNK-IN-8 may be superior to pevonedistat alone, and
thus we are currently exploring this possibility.
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